SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories informs about company updates

30 Mar 2017 Evaluate

In furtherance to the intimation captioned Update on US FDA Inspection at Alkems Ankaleshwar API Facility dated 12th December, 2016; Alkem Laboratories has informed that the US FDA has issued an Establishment Inspection Report (EIR) for the Company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at Ankaleshwar, India which was inspected in December 2016. The inspection has now been closed by the US FDA. In response to the Form 483 issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The US FDA has reviewed the CAPA and has found them acceptable.

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories Share Price

5634.80 51.10 (0.92%)
20-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 935.00
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×